Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been given a consensus recommendation of "Buy" by the seven brokerages that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.67.

Several research firms have recently issued reports on AQST. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Lake Street Capital dropped their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Finally, Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th.

Aquestive Therapeutics Trading Up 2.8 %

NASDAQ AQST traded up $0.08 on Friday, hitting $2.92. 1,002,979 shares of the company's stock traded hands, compared to its average volume of 1,480,006. The firm has a market capitalization of $288.70 million, a PE ratio of -6.49 and a beta of 2.59. Aquestive Therapeutics has a 1-year low of $2.20 and a 1-year high of $5.80. The firm's 50-day moving average price is $2.78 and its two-hundred day moving average price is $3.59.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. On average, research analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Aquestive Therapeutics during the 1st quarter worth $33,000. New York State Common Retirement Fund raised its stake in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after purchasing an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Aquestive Therapeutics during the fourth quarter worth about $44,000. Two Sigma Advisers LP acquired a new position in Aquestive Therapeutics in the 4th quarter valued at about $57,000. Finally, PKS Advisory Services LLC purchased a new stake in shares of Aquestive Therapeutics in the 4th quarter valued at approximately $63,000. Hedge funds and other institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.